The company said its products are also informing surgery and treatment decision-making using the same minimally invasive patient sample, according to a statement.
"Our RNA platform uniquely enables our Afirma offering to answer important clinical questions that can guide various points in a patient's journey, helping to improve outcomes," CEO Bonnie Anderson said. "Further, by providing this comprehensive information from the original biopsy used in diagnosis, we can streamline workflows and enable patients to get the answers they need faster and more easily."
Shares rose by more than 3% intraday.
Price: 28.42, Change: +0.85, Percent Change: +3.10
|VMware Q2 Results Top Street Expectations|
|Amazon.com Buys 49% Stake in Future Coupon|
|Research Alert: CFRA Maintains Buy Opinion On Shares...|
|--CenturyLink Keeps Quarterly Dividend at $0.25/Shar...|
|Insider Trends: Insider Sales Continue 90-Day Trend ...|